No Data
No Data
Interpretation of ESG Annual Report|Yisheng Biotechnology (01061) Releases 2023 ESG Report Greenhouse Gas Density Decreased by 33.3% YoY
Zhitong Finance App News. Recently, Yisheng Biotechnology (01061) released the “2023 Environmental, Social and Governance Report”, which sets out the Group's strategies and practices in the three areas of environmental protection, social responsibility and operational governance for the year ended December 31, 2023, covering the business operated by the Group. According to reports, Yisheng Biotechnology is mainly engaged in manufacturing, sales, marketing and distribution of pharmaceuticals, and its main operating area is China. According to the ESG report, the board of directors of Yisheng Biotech bears full responsibility for the company's ESG strategy and ESG report, and is responsible for evaluating and determining ESG-related risks and
ESSEX BIO-TECH: ANNUAL REPORT 2023
ESSEX BIO-TECH To Go Ex-Dividend On May 30th, 2024 With 0.045 HKD Dividend Per Share
March 19th - $ESSEX BIO-TECH(01061.HK)$ is trading ex-dividend on May 30th, 2024. Shareholders of record on May 31st, 2024 will receive 0.045 HKD dividend per share on June 17th, 2024. The ex-divi
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology's (HKG:1061) profit increased 22.1% to HK$275.3 million, or HK$0.469 per share, in 2023, from HK$225.4 million, or HK$0.3828 per share, in 2022, according to a Monday filing with
Gelonghui Announcements Selected (Hong Kong Stock) | Reading Group (00772.HK) Announces Annual Results Monthly Paying User Growth of Its Own Platform Products by Over 20%, Officially Entering the Boutique Short Drama Market
[Today's Focus] Reading Text Group (00772.HK) announced its annual results, with monthly paying users of its platform products growing by more than 20%. Reading Group (00772.HK) announced that for the year ended December 31, 2023, the company's revenue reached RMB 7,011.8 million, and the profit attributable to the company's equity holders increased 32.3% year-on-year to RMB 804.9 million. The average monthly paying users of the company's own platform products and self-operated channels increased 10.1% year-on-year from 7.9 million to 8.7 million in the same year. In particular, the company's own platform
Yisheng Biotechnology (01061.HK)'s profit in 2023 increased 22.1% year-on-year to approximately HK$275.3 million
Gelonghui, March 18, 丨 Yisheng Biotechnology (01061.HK) announced that for the year ended December 31, 2023, the Group recorded a consolidated turnover of approximately HK$1,707 billion, an increase of 29.5% over the previous year. Accordingly, the Group's profit increased by 22.1% compared to 2022 to approximately HK$275.3 million, which was particularly hampered by the resulting withholding tax. After considering the full conversion of convertible loans, the basic and diluted earnings per share attributable to the owners of the company were HK$48.27 and HK46.90 cents, respectively. The Group's vision is to become a great company with a sense of social responsibility. In terms of business strategy,
No Data
Syuee : Penny stocks are the realm of dreams and nightmares for speculators.
HopeAlways : Penny stocks are speculative in nature, and tend to more volatile; more suited for day trading and those who can stomach higher risks.
HuatEver : I started my trading journey with Penny Storks, well guided by a sharp witted mentor. This “1st pot of gold” has got me “hooked” on to Moomoo’s trading platform.
HuatLadyOP HuatEver: A very auspicious beginning to add to your trading portfolio.
HuatLadyOP HopeAlways: I reckon you have blacklisted penny stocks trading as red flags.
View more comments...